Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2005-08-16
2005-08-16
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S449000, C514S974000
Reexamination Certificate
active
06929801
ABSTRACT:
The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.
REFERENCES:
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 4299826 (1981-11-01), Luedders
patent: 4440777 (1984-04-01), Zupan
patent: 4557934 (1985-12-01), Cooper
patent: 4704406 (1987-11-01), Stanislaus
patent: 4820724 (1989-04-01), Nimni
patent: 4954487 (1990-09-01), Cooper et al.
patent: 5034386 (1991-07-01), Peck et al.
patent: 5036100 (1991-07-01), Deboeck et al.
patent: 5082656 (1992-01-01), Hui et al.
patent: 5082866 (1992-01-01), Wong et al.
patent: 5122519 (1992-06-01), Ritter
patent: 5256647 (1993-10-01), Minaskanian et al.
patent: 5487898 (1996-01-01), Lu et al.
patent: 6299900 (2001-10-01), Reed et al.
patent: 30258/89 (1989-09-01), None
patent: 49984/1990 (1989-09-01), None
patent: 91413/91 (1992-06-01), None
patent: 43 34 553 (1995-04-01), None
patent: 189 861 (1986-08-01), None
patent: 61-268631 (1986-11-01), None
patent: 92/19271 (1992-11-01), None
patent: 96/30000 (1996-10-01), None
R.J. Feldmann et al., “Arch Derm”, vol. 94,Percutaneous Penetration of 14C Hydrocortisone in Man, pp. 649-651 (Nov. 1966).
M. F. Coldman et al., “Journal of Pharmaceutical Sciences”, vol. 58, No. 9,Enhancement of Percutaneous Absorption by the Use of Volatile: Nonvolatile Systems and Vehicles, pp. 1098-1102 (Sep. 1969).
P.P. Bhatt et al., “International Journal of Pharmaceutics” 50,Finite dose transport of drugs in liquid formulations through stratum corneum: analytical solution to a diffusion model, pp. 197-203 (1989).
Nimni, U.S. Appl. No. 4,820,742, Internet: www.patents.ibm. com/fegi-bin/any2htm Document,Dual Phase Solvent Carrier System, pp. 3, 4 and 6 out of 7 pages.
Journal Of Toxicology and Environmental Health, Bucks, D.A., et al., Percutanteus Absorption of Hydroquinone in Humans: Effect of 1-Dodecylazacycloheptan-2-One (Azone) and the 2-Ethylhexyl Ester of 4-(Dimethylamino) Benzoic Acid (Escalol 507), vol. 24, pp. 27-289 (1988).
Physician's Desk Reference, PDR 51 Ed., 1997, pp. 1299-1300.
Finnin Barrie Charles
Klose Kathryn Traci-Jane
Morgon Timothy Matthias
Reed Barry Leonard
Tran Ngan Thi Kim
Acrux DDS PTY LTD
Dodson Shelley A.
Foley & Lardner LLP
George Konata M.
LandOfFree
Transdermal delivery of antiparkinson agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal delivery of antiparkinson agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal delivery of antiparkinson agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523809